Turn Therapeutics Inc. appointed Robert R. Redfield, M.D., as Chief Scientific Officer on September 9, 2026. Dr. Redfield brings over four decades of experience in immunology and public health, including service as the former Director of the U.S. Centers for Disease Control and Prevention. In this role, he will contribute to the scientific strategy for lead candidate GX-03 across indications such as atopic dermatitis, onychomycosis, and hidradenitis suppurativa. Turn Therapeutics Inc. is a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases.

Turn Therapeutics Inc. issued 579,664 shares of common stock to GEM Yield Bahamas Limited on August 13, 2026, following the full cashless exercise of a warrant for 1,192,207 shares. The transaction relied on Section 4(a)(2) registration exemption based on the investor's accredited status. Turn Therapeutics Inc. operates in the biotechnology industry, focusing on drug discovery and development.

On August 14, 2026, Turn Therapeutics Inc. entered into securities purchase agreements with accredited investors to issue and sell 135,000 shares of common stock at $10.00 per share, generating aggregate gross proceeds of $1.35 million. The transaction was conducted as a private placement under Section 4(a)(2) of the Securities Act and Regulation D, with registration rights granted to the investors. Turn Therapeutics Inc. operates in the biotechnology industry, focusing on drug discovery and development.

Turn Therapeutics Inc. reported financial and operating results for the quarter ended June 30, 2026. The company announced that interim Phase 2 data for its lead candidate GX-03 in atopic dermatitis showed activity across a broader patient population than anticipated, prompting an expansion of Stage 2 enrollment to approximately 120–135 patients with moderate-to-severe lesions but lower overall disease extent. Turn Therapeutics appointed former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical and Regulatory Lead on May 18, 2026. Financially, the company reported a net loss of $5.8 million for the quarter, with cash and cash equivalents totaling $10.3 million as of June 30, 2026, providing operational runway into the third quarter of 2027. The company also plans to expand GX-03 development into hidradenitis suppurativa, targeting first patient dosing in Q2 2027. Turn Therapeutics is a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases.

Turn Therapeutics Inc. filed a Form 8-K on July 28, 2026, to furnish an updated investor presentation under Item 7.01 of Regulation FD. The presentation outlines the company's pipeline, including GX-03 for moderate-to-severe atopic dermatitis, with Phase 2 topline results expected in Q4 2026. It also details plans for Phase 3 trials in onychomycosis starting in Q1 2027 and Phase 2a trials in hidradenitis suppurativa in Q2 2027. Financial highlights include a cash balance of $11.2 million as of March 31, 2026, and a cash runway extending into Q3 2027. Turn Therapeutics Inc. operates in the biotechnology industry, developing precision immunomodulation therapies for inflammatory skin diseases.